### Treatment OfInfraorbital Dark Circles Using Long-Pulsed 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser

#### **A Thesis**

Submitted for Partial Fulfillment of Master Degree in Dermatology, Venereology and Andrology

#### Presented by

#### DINA REDA MOHAMMED

M.B.B.Ch, Ain Shams University

### **Under Supervision of**

### Prof. Mohammed ABD El NaeemSallam

Professor of Dermatology ,Venereology and Andrology Faculty of Medicine, Ain Shams University

### Dr \ Mahmoud Abd El Rahim Abdallah

Associate Professor of Dermatology, Venereology and Andrology Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University 2015



My deepest gratitude and thanks to **ALLAH** the most Merciful for guiding me through and giving me the strength to complete this work the way it is.

I wish to express my deepest thanks and gratitude to Prof. Dr. Mohammed ABD ElnaeemSallamwho gave me the honor of working under his supervision, continuous guidance and valuable advice throughout the work. He offered me his support and patience, enriching me with his vast experience and continuous advices which helped me to overcome any difficulty.

I would like to express my deepest gratitude and special thanks to, Dr. Mahmoud Abd El Rahim Abdallah, Associate Professor of Dermatology, Venereology and Andrology Faculty of Medicine, Ain Shams University for his close observation, generous guidance, effective help, and valuable supervision.

Finally, it is a great honor to me to express my deepest gratitude, extreme thankfulness and deep appreciation to my Family who helped me a lot to complete this work.

≥Dina Reda Mohammed

# List of contents

| Contents  | Page |
|---|------|
| Introduction                                    | 1    |
| Aim of the work                                 | 3    |
| Chapter (1): Causes of Infraorbital dark circle | 4    |
| Chapter (2): Treatment of dark circles          | 29   |
| Chapter (3): Patients and Methods               | 55   |
| Chapter (4): Results                            | 59   |
| Chapter (5): Discussion                         | 67   |
| Summary   | 72   |
| Conclusion                                      | 75   |
| References                                      | 76   |
| Arabic summary                                  |      |

# List of Figures

| Figure        |                                       | Page |
|---------------|---------------------------------------|------|
| Figure (1.1)  | Schematic presentation of a           | 6    |
|               | melanocyte                            |      |
| Figure (1.2)  | Periorbital hyper- pigmentation of    | 15   |
|               | vascular pattern.                     |      |
| Figure (1.3)  | Eyelid vasculature                    | 17   |
| Figure (2.1)  | Dark circles due to tear trough       | 52   |
|               | depression before and after           |      |
|               | blepharoplasty                        |      |
| Figure (4.1)  | Theclearance score according to the   | 59   |
|               | number of sessions                    |      |
| Figure (4.2)  | The relation between number of        | 62   |
|               | treatment sessions and patient        |      |
|               | satisfaction                          |      |
| Figure (4.3a) | Patient( A) before starting treatment | 63   |
|               | sessions                              |      |
| Figure(4.3b)  | Patient (A )after finishing three     | 63   |
|               | sessions on left eye                  |      |
| Figure (4.4a) | Patient (B) before starting treatment | 64   |
|               | sessions.                             |      |
| Figure(4.4b)  | Patient (B) after finishing two       | 64   |
|               | treatment sessions on her left eye    |      |
| Figure (4.5a) | Patient (C) before starting treatment | 65   |
|               | sessions                              |      |
| Figure(4.5b)  | Patient (C) after finishing three     | 65   |
|               | treatment sessions on her left eye.   |      |

| Figure (4.6a) | Patient (D) before starting treatment | 66 |
|---------------|---------------------------------------|----|
|               |                                       |    |
| Figure(4.6b)  | Patient (D) after finishing three     | 66 |
|               | sessions on her left eye.             |    |

# List of Tables

| Table       |  | Page |
|-------------|--|------|
| Table(2. 1) | Different types of lasers and available parameters used in treatment of infraorbital dark circles. | 49   |
| Table (4.1) | The clearance score according to the number of sessions  | 59   |
| Table (4.2) | Patients' age, family history, number of sessions, clearance and patient satisfaction score.       | 60   |
| Table (4.3) | Pain score among patients.   | 61   |
| Table (4.4) | Patient satisfaction   | 61   |
| Table (4.5) | The relation between number of treatment sessions and patient satisfaction                         | 62   |

## List of abbreviations

| ACD:           | Allergic contact dermatitis.             |
|----------------|--|
| ACTH:          | Adrenocorticotropic hormone.             |
| AD:            | Atopic dermatitis.                       |
| AHA:           | Alpha hydroxy acid.                      |
| BaSo4:         | Barium sulfate.                          |
| <b>BFGF:</b>   | Basic fibroblast growth factor           |
| B-MSH:         | Beta melanin stimulating hormone.        |
| Co2:           | Carbon dioxide.                          |
| CW co2:        | Continuous wave carbon dioxide.          |
| DA:            | Deoxy-arbutin                            |
| DC:            | Dark circles.                            |
| DCT:           | Dihydroxy-L-phenylalanie chrome          |
|                | tautomerase.                             |
| DOPA:          | Dihydroxyphenylalanine.                  |
| EGF:           | Epithelial growth factor                 |
| ER:            | Endoplasmic reticulum.                   |
| Er:YSGG:       | Erbium: yttrium scandium gallium garnet  |
|                | laser.                                   |
| ET-1:          | Endothelin-1.                            |
| FDE:           | Fixed drug eruption.                     |
| <b>GM-CSF:</b> | Granulocyte-macrophage colony-           |
|                | stimulating factor.                      |
| HGF:           | Hepatocyte growth factor.                |
| ICD:           | Irritant contact dermatitis.             |
| ICHOR:         | Idiopathic cutaneous hyperchromia of the |
|                | orbital region.                          |
| IOP:           | Infraorbital pigmentation.               |
| KA:            | Kojic acid.                              |

| KTP:         | Potoggium titonyl phogphoto          |
|--------------|--------------------------------------|
|              | Potassium-titanyl-phosphate.         |
| LA:          | Lactic acid.                         |
| LIF:         | Leukemia inhibitory factor.          |
| LP:          | Long pulse.                          |
| MC1-R:       | Melanocortin 1 receptor.             |
| MgO:         | Magnesium oxide.                     |
| MS:          | Millisecond.                         |
| MSH:         | Melanin stimulating hormone.         |
| NGF:         | Nerve growth factor.                 |
| ND: YAG:     | Neodymium-doped yttrium aluminum     |
|              | garnet.                              |
| NS:          | Nanosecond.                          |
| PABA:        | Para-aminobenzoic acid.              |
| PBC:         | Primary biliary cirrhosis.           |
| <b>PDGF:</b> | Platelet-derived growth factor       |
| PG:          | Prostaglandins.                      |
| PIH:         | Post inflammatory hyperpigmentation. |
| PKC:         | Protein kinase C.                    |
| <b>POMC:</b> | Proopiomelanocortin                  |
| POH:         | Periocular hyperpigmentation.        |
| PRP:         | Platelets rich plasma.               |
| QS:          | Quality switched.                    |
| QSNY:        | Quality-switched neodymium doped     |
|              | yttrium.                             |
| RA:          | Retinoic acid.                       |
| TGF:         | Transforming growth factor.          |
| TiO2:        | Titanium dioxide.                    |
| TYR:         | Tyrosinase.                          |
| TYRP1:       | Tyrosinase-related protein 1         |
| VEGF:        | Vascular endothelial growth factor.  |

| ZnO: | Zinc oxide. |  |
|------|-------------|--|
|------|-------------|--|

علاج الهالات السوداء تَحْت الحَجاج باستخدام الليزر البِجادِيّ من الألومينيوم ذي الإتريوم القائم على شبه موصل مطلي بالنِيُوديميُوم ( 1,064 نانومتر) طويل النبض

رسالة

توطئة للحصول على درجة الماجستير في الأمراض الجلدية والتناسلية وأمراض الذكورة

مقدمه من الطبيبة/ دينا رضا محمد بكالوريوس الطب والجراحة - جامعة عين شمس

تحت إشراف أ.د./ محمد عبد النعيم سلام

أستاذالأمراض الجلدية والتناسلية وأمراض الذكورة كلية الطب - جامعة عين شمس

د./ محمود عبد الرحيم عبد الله

أستاذ مساعد الأمراض الجلدية والتناسلية وأمراض الذكورة كلية الطب - جامعة عين شمس

كلية الطب جامعة عين شمس

### Introduction

Infraorbital dark circle refers to a condition that presents with relative darkness of the infraorbital eyelids. It can be a significant cosmetic problem, and many individuals seek treatment for this condition, but there have been few investigations regarding the cause and little research into the potential treatment of this condition, moreover it worsens with the aging process of skin sagging and altered subcutaneous fat distribution (*Yaar and Gilchrest*, 2001).

Possible causative factors of the dark circles include excessive pigmentation; thin, translucent lower eyelid skin overlying the orbicularis oculi muscle; and shadowing due to skin laxity and tear trough (*Lowe et al.*, 1995).

In general, treatment with depigmenting agents must be continued for several months before cosmetic benefits are obtained. The action mechanisms of depigmenting agents are inhibition of tyrosinase activity, inhibition of DNA synthesis in hyperactive melanocytes, reduction of epidermal content of melanin, and thickening of the epidermis (granular layer)(*Prignano et al.*, 2007).

If infraorbital dark circles are due to thin and translucent lower eyelid skin, the prominence of the infraorbital veins makes them visible. In this case the use of sclerotherapy for the removal of periocular veins is unsuitable because of the risk of ophthalmologic and neurologic complications (*Kersten et al.*, 2007).

Dark circles due to excessive pigmentation have been successfully treated with various pigment lasers, including the Q-switched ruby (694-nm) laser (*Lowe et al.*,1995), Q-switched alexandrite (755-nm) laser, and neodymium-

doped yttrium aluminium garnet (Nd:YAG) 1,064-nm laser (Kovak etal.,1998).

Variable-pulsed neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers have been used for the effective removal of telangiectasias and leg veins (*Bevin et al.*,2006).

Long- pulsed 1,064 (Nd:YAG) laser was successfully used for the treatment of infraorbital dark circles due to visible prominent veins which found to be effective and safe (*Ma et al.*, 2012)no control was used in this study.

## Aim of the Work

To assess the effectiveness of Long-Pulsed 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser in the treatment of venous infraorbital dark circles.

### **Chapter 1**

### **Causes of Infraorbital Dark Circles**

### 1.1. Definition of dark circles:

Dark circle is not a formal medical term, but both patients and dermatologists use it to indicate periorbital hyperchromic macules and patches (*Balkrishnan et al.*, 2003). Dark circles also known as idiopathic cutaneous hyperchromia of the orbital region (ICHOR), periorbital hyperpigmentation, periorbital melanosis or infraorbital pigmentation (*Epstein*, 1999).

Infraorbital dark circles interfere with the face appearance, giving the patient a tired, sad, or hung over look. Women tend to find this condition particularly problematic, and many urgently seek treatment for it (*Freitag and Cestari*, 2007). This condition is relatively common affecting individuals regardless age, sex, and race (*Roh andChung*, 2009). Moreover, it worsens with the aging process of skin sagging and altered subcutaneous fat distribution (*Yaar and Gilchrest*, 2001).

Although dark circles is a condition that does not cause morbidity, it can influence the quality of life from the medical point of view (*Balkrishnan et al.*, 2003).

### 1.2. Pathogenesis of Skin Pigmentation:

Cutaneous pigmentation is the outcome of two important events:the synthesis of melanin by melanocytes within melanosomes and the transfer ofmelanosomes via dendrites (membrane-boundorganelles) to surrounding keratinocytes, wherethey play a critical role in photoprotection (*Costinand Hearing*, 2007).

The melanin contentof human melanocytes heterogeneous not only between differentskin types which are highly regulated by gene expression, but also between different sites of the skin from the same individual for example: face. and shins (James al.. arms **2006**). Variation skin pigmentation is in multifactorial traitwith numerous intrinsic and extrinsic factors, including a number of major genetic determinants, gender effects, hormonal effects, age, stress, environmental effects such as exposure to ultra violet rays(UVR) and chemical exposure that modulate the amount, type, and distribution of melanin in the skin (Schoen and Lazar, *1990*).

### 1.2.1. Melanin biosynthesis:

Melanin biosynthesis is a complex pathway that appears within melanosomes in melanocytes which are highlyspecialized cells (Kanitakis, 2002). Melanosomes are typically divided into four maturation stages(Figure 1.1) by determined their (I–IV) structure the quantity, quality, and arrangement of the melanin produced (Kushimoto et al., 2001).